Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of $12.58 billion. The enterprise value is $9.67 billion.
| Market Cap | 12.58B |
| Enterprise Value | 9.67B |
Important Dates
The next estimated earnings date is Thursday, May 1, 2025.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 63.54 million shares outstanding. The number of shares has decreased by -1.95% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 63.54M |
| Shares Change (YoY) | -1.95% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 62.86M |
Valuation Ratios
The trailing PE ratio is 1.15 and the forward PE ratio is 14.30.
| PE Ratio | 1.15 |
| Forward PE | 14.30 |
| PS Ratio | 4.21 |
| Forward PS | 0.50 |
| PB Ratio | 2.47 |
| P/TBV Ratio | 4.15 |
| P/FCF Ratio | 11.44 |
| P/OCF Ratio | 11.66 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.43, with an EV/FCF ratio of 8.79.
| EV / Earnings | 8.88 |
| EV / Sales | 3.24 |
| EV / EBITDA | 9.43 |
| EV / EBIT | 9.84 |
| EV / FCF | 8.79 |
Financial Position
The company has a current ratio of 5.25, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.25 |
| Quick Ratio | 5.24 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.14 |
| Debt / FCF | 0.13 |
| Interest Coverage | 58.99 |
Financial Efficiency
Return on equity (ROE) is 22.97% and return on invested capital (ROIC) is 12.62%.
| Return on Equity (ROE) | 22.97% |
| Return on Assets (ROA) | 10.91% |
| Return on Invested Capital (ROIC) | 12.62% |
| Return on Capital Employed (ROCE) | 17.48% |
| Revenue Per Employee | $1.12M |
| Profits Per Employee | $406,617 |
| Employee Count | 2,678 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 16.55 |
Taxes
In the past 12 months, Genmab has paid $183.25 million in taxes.
| Income Tax | 183.25M |
| Effective Tax Rate | 14.40% |
Stock Price Statistics
The stock price has decreased by -35.14% in the last 52 weeks. The beta is 0.90, so Genmab's price volatility has been similar to the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | -35.14% |
| 50-Day Moving Average | 20.86 |
| 200-Day Moving Average | 23.43 |
| Relative Strength Index (RSI) | 39.70 |
| Average Volume (20 Days) | 1,484,459 |
Short Selling Information
The latest short interest is 3.06 million, so 0.49% of the outstanding shares have been sold short.
| Short Interest | 3.06M |
| Short Previous Month | 2.31M |
| Short % of Shares Out | 0.49% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.98 |
Income Statement
In the last 12 months, Genmab had revenue of $2.99 billion and earned $1.09 billion in profits. Earnings per share was $16.85.
| Revenue | 2.99B |
| Gross Profit | 2.85B |
| Operating Income | 982.72M |
| Pretax Income | n/a |
| Net Income | 1.09B |
| EBITDA | 1.03B |
| EBIT | 982.72M |
| Earnings Per Share (EPS) | $16.85 |
Balance Sheet
The company has $2.93 billion in cash and $142.85 million in debt, giving a net cash position of $2.79 billion or $43.85 per share.
| Cash & Cash Equivalents | 2.93B |
| Total Debt | 142.85M |
| Net Cash | 2.79B |
| Net Cash Per Share | $43.85 |
| Equity (Book Value) | 5.09B |
| Book Value Per Share | 80.18 |
| Working Capital | 3.13B |
Cash Flow
In the last 12 months, operating cash flow was $1.08 billion and capital expenditures -$25.96 million, giving a free cash flow of $1.10 billion.
| Operating Cash Flow | 1.08B |
| Capital Expenditures | -25.96M |
| Free Cash Flow | 1.10B |
| FCF Per Share | $17.31 |
Margins
Gross margin is 95.42%, with operating and profit margins of 32.89% and 36.44%.
| Gross Margin | 95.42% |
| Operating Margin | 32.89% |
| Pretax Margin | 42.57% |
| Profit Margin | 36.44% |
| EBITDA Margin | 34.33% |
| EBIT Margin | 32.89% |
| FCF Margin | 36.82% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.95% |
| Shareholder Yield | 1.95% |
| Earnings Yield | 8.65% |
| FCF Yield | 8.74% |
Analyst Forecast
The average price target for Genmab is $40.00, which is 105.81% higher than the current price. The consensus rating is "Buy".
| Price Target | $40.00 |
| Price Target Difference | 105.81% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 13.39% |
| EPS Growth Forecast (5Y) | 9.88% |
Stock Splits
The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.
| Last Split Date | May 1, 2018 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
Genmab has an Altman Z-Score of 10.02 and a Piotroski F-Score of 4.
| Altman Z-Score | 10.02 |
| Piotroski F-Score | 4 |